The United
Kingdom Colorectal Cancer Therapeutics Market is expected to witness
significant growth during the projected period of 2028. Colorectal cancer, a
prevalent public health concern in the United Kingdom, affects the colon or
rectum. However, thanks to the country's robust healthcare system and dedicated
research and development efforts, advancements in colorectal cancer therapeutics
have been achieved. The United Kingdom's colorectal cancer therapeutics market
has experienced substantial growth, driven by innovative treatments, targeted
therapies, and early detection methods that have revolutionized patient care
and improved survival rates.
Colorectal
cancer typically originates in the colon (large intestine), where abnormal
growths or polyps in the inner lining can lead to the development of cancer.
Precancerous polyps can be identified through screening tests performed by
healthcare professionals before they progress into cancerous tumors. Timely
diagnosis and treatment of colorectal cancer are crucial to prevent its spread
to other parts of the body. Fortunately, the implementation of screening tests,
early treatment, and innovative therapies has resulted in fewer deaths from
colorectal cancer. The United Kingdom's colorectal cancer therapeutics market
has witnessed the introduction of various innovative therapies aimed at
providing better outcomes and improving patients' quality of life. Notably,
targeted therapies have garnered significant attention. By focusing on specific
molecular and genetic abnormalities present in cancer cells, targeted therapies
offer more precise and effective treatments. Monoclonal antibodies and small
molecule inhibitors are examples of such therapies, which have shown promise in
improving survival rates and reducing the side effects associated with
traditional chemotherapy.
According
to the Office for National Statistics, the healthcare cost in the United Kingdom
was estimated to be approximately USD350.83 billion in 2022, representing a
nominal increase of 0.7% compared to 2021.
Rising Prevalence of Colorectal Cancer Will Spur the Demand for
Colorectal Cancer Therapeutics
The United Kingdom is facing a significant burden of
colorectal cancer, a devastating disease that claims numerous lives each year.
According to the UK Colorectal Cancer Intelligence Hub, colorectal cancer
affects over 41,000 people annually in the United Kingdom, with 16,000 deaths
resulting from it. The incidence of colorectal cancer has been steadily
increasing over the past few decades, attributed to factors such as sedentary
lifestyles, unhealthy dietary habits, obesity, and an aging population. Colorectal
cancer arises when cells undergo uncontrolled growth and division, similar to
other types of cancer. Normally, the body's cells continuously divide, grow,
and die, maintaining overall health and functionality. However, in colon
cancer, the cells lining the colon and rectum continue to grow and divide
instead of dying as they should. These cancerous cells may originate from colon
polyps. Improved screening methods and increased awareness have led to early
detection, resulting in a higher number of reported cases and expanding the
United Kingdom Colorectal Cancer Therapeutics Market. The rising prevalence of
colorectal cancer has driven the development and advancement of various
treatment modalities within the market, including surgery, radiation therapy,
chemotherapy, targeted therapies, immunotherapies, and supportive care.
Targeted therapies and immunotherapies, such as monoclonal antibodies and
immune checkpoint inhibitors, have revolutionized the treatment landscape by
offering more personalized and effective options. Precision medicine has gained
significant momentum in the field of colorectal cancer treatment, enabling
clinicians to identify specific biomarkers that determine a patient's response
to certain therapies through molecular profiling and genetic testing
techniques. This approach allows for tailored treatment plans, minimizing
unnecessary side effects and optimizing therapeutic outcomes. The increasing
availability and affordability of genomic profiling technologies have further
facilitated the adoption of precision medicine in the management of colorectal
cancer, thereby driving the anticipated growth of the United Kingdom Colorectal
Cancer Therapeutics Market in the forecast period.
Rising Geriatric
Population Drives the United Kingdom Colorectal Cancer Therapeutics Market
The United Kingdom is currently undergoing a significant demographic
shift, characterized by a rapidly aging population. With the number of elderly
individuals on the rise, the prevalence of age-related diseases, such as
colorectal cancer, is also increasing. This demographic trend has far-reaching
implications for the healthcare system, particularly in the field of cancer
therapeutics. The United Kingdom Colorectal Cancer Therapeutics Market is
experiencing substantial growth, driven by the growing geriatric population and
the subsequent demand for effective treatment options. According to the
Organization for Economic Co-operation and Development (OECD), the proportion
of elderly people in the total population of the United Kingdom is 18.83%. The
geriatric population is particularly susceptible to developing colorectal
cancer due to various factors, including age-related changes in the digestive
system, genetic predisposition, and lifestyle choices. Consequently, there is
an urgent need for advanced therapeutics to effectively treat colorectal cancer
and improve patient outcomes. This demand has prompted extensive research and
development activities in the pharmaceutical industry, leading to the
introduction of innovative treatment options. The United Kingdom Colorectal
Cancer Therapeutics Market encompasses a wide range of therapies, including
surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.
Surgical interventions remain the primary treatment option for localized
colorectal cancer, aiming to remove the tumor and affected tissues. However,
for advanced stages of the disease, a multidisciplinary approach involving
chemotherapy and radiation therapy is often employed. Furthermore, the
increasing geriatric population has necessitated greater investment in
healthcare infrastructure and research initiatives. Government bodies and
healthcare organizations are actively supporting clinical trials and research
studies to enhance the understanding of colorectal cancer and develop new
treatment modalities. This collaborative effort between academia, industry, and
healthcare providers is crucial in advancing the field of colorectal cancer
therapeutics and improving patient outcomes. Additionally, the growing
awareness of colorectal cancer and the demand for improved therapeutics have
fostered collaborations among researchers, pharmaceutical companies, and
healthcare providers. These partnerships have accelerated the development of
innovative treatment options and facilitated access to advanced therapies for
patients. By leveraging collective expertise and resources, these
collaborations are driving progress in the fight against colorectal cancer,
thereby bolstering the growth of the United Kingdom Colorectal Cancer
Therapeutics Market. As reported by the Office for National Statistics, the
statistical results for 2021 indicate that the population of England and Wales
continues to age, with a notable increase in the number of individuals in older
age categories. Nearly 11 million people, or 18.6% of the total population,
are now 65 years of age or older, compared to 16.4% during the previous census
in 2011. Among this group, there are 527,900 individuals who are at least 90
years old.
Recent Developments
- According to the
results of a clinical trial funded by Cancer Research UK and conducted by
the Universities of Birmingham and Leeds in March 2023, administering
chemotherapy to colon cancer patients before surgery has been shown to
decrease the likelihood of disease recurrence. The FOxTROT trial revealed
that administering the first six weeks of chemotherapy prior to surgery,
as opposed to after, reduces the risk of cancer recurrence within two
years by 28%.
Mergers and Acquisitions
- In October
2022, a clinical trial partnership and supply agreement between Erasca and
Pfizer focused on Palbociclib (Ibrance), a CDK4/6 inhibitor. The aim is to
address colorectal cancer (CRC) and pancreatic ductal adenocarcinoma
(PDAC) with KRAS- and NRAS-mutations, through a clinical proof-of-concept
trial using ERAS-007 in combination with Palbociclib.
- Furthermore,
in March 2023, Pfizer allocated USD43 billion for the acquisition of
Seagen, thereby expanding its capabilities in cancer treatment.
- Additionally, in August 2022, Eli
Lilly & Company collaborated with ERASCA to investigate the
combination of ERAS-601 and Cetuximab for the treatment of metastatic
colorectal cancer.
Market Segmentation
United Kingdom Colorectal
Cancer Therapeutics Market is segmented into Drug Class, End User, Region and
Competitive Landscape. Based on Drug Class, the Market is divided into Chemotherapy,
Immunotherapy and Others. Based on End User, the market is categorized into Hospitals,
Clinics and Others. Based on region, the United Kingdom Colorectal Cancer
Therapeutics Market is segmented into Scotland, South-East, London, South-West,
East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Novartis AG, Pfizer Inc,
Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca
Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Roche Holding
AG are some of the key players in the United Kingdom Colorectal Cancer Therapeutics
market.
Download Free Sample Report
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, volume
forecasting, Company shares, competitive landscape, growth factors, and
trends
|
|
Segments
covered
|
Drug
Class
End
User
Region
|
|
Country scope
|
Scotland, South-East,
London, South-West, East-Anglia, Yorkshire & Humberside, and East
Midlands
|
|
Key companies profiled
|
Novartis
AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc.,
GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai
Co., Ltd., Sanofi S.A., Roche Holding AG
|
|
Customization
scope
|
10% free report customization with purchase. Addition or alteration
to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase
options to meet your exact research needs.
|
|
Delivery
Format
|
PDF and Excel through Email (We can
also provide the editable version of the report in PPT/Word format on special
request)
|
Report Scope:
In this report, United Kingdom Colorectal Cancer Therapeutics
Market has been segmented into the following categories, in addition to the
industry trends, which have also been detailed below:
- United Kingdom Colorectal Cancer Therapeutics
Market, By Drug Class:
- Chemotherapy
- Immunotherapy
- Others
- United Kingdom Colorectal Cancer
Therapeutics Market, By End User:
- United Kingdom Colorectal Cancer Therapeutics
Market, By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire & Humberside
- East Midlands
Competitive landscape
Company Profiles: Detailed analysis of the major companies in United
Kingdom Colorectal Cancer Therapeutics market.
Available Customizations:
With the
given market data, TechSci Research offers customizations according to a company’s
specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
United Kingdom Colorectal
Cancer Therapeutics Market is an upcoming report to be released soon. If you wish
an early delivery of this report or want to confirm the date of release, please
contact us at [email protected]